Literature DB >> 9249646

COX-1 and COX-2 tissue expression: implications and predictions.

L J Crofford1.   

Abstract

It has been proposed that cyclooxygenase (COX)-1 and COX-2 subserve different physiologic functions largely because of the striking differences in their tissue expression and regulation. COX-1 displays the characteristics of a "housekeeping" gene and is constitutively expressed in almost all tissues. COX-1 appears to be responsible for the production of prostaglandins (PG) that are important for homeostatic functions, such as maintaining the integrity of the gastric mucosa, mediating normal platelet function, and regulating renal blood flow. In sharp contrast, COX-2 is the product of an "immediate-early" gene that is rapidly inducible and tightly regulated. Under basal conditions, COX-2 expression is highly restricted; however, COX-2 is dramatically upregulated during inflammation. For example, synovial tissues in patients with rheumatoid arthritis (RA) express increased levels of COX-2. In animal models of inflammatory arthritis, COX-2 increases in parallel with PG production and clinical inflammation. In vitro experiments have revealed increased COX-2 expression after stimulation with proinflammatory cytokines, such as interleukin 1 (IL-1) and tumor necrosis factor-alpha (TNF-alpha), in many cell types, including synoviocytes, endothelial cells, chondrocytes, osteoblasts, and monocytes/macrophages. Another distinguishing characteristic of COX-2 is decreased expression in response to glucocorticoids. COX-2 is also increased in some types of human cancers, particularly colon cancer. Mechanisms underlying the association between COX-2 overexpression and tumorigenic potential may include resistance to apoptosis, or programmed cell death. Upregulated COX-2 expression undoubtedly plays a role in pathologic processes characterized by increased local PG production. One would predict, based on current information regarding the differential tissue expression of COX-1 and COX-2, that highly selective inhibitors of COX-2 will provide effective antiinflammatory activity with marked reduction in toxicity.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9249646

Source DB:  PubMed          Journal:  J Rheumatol Suppl        ISSN: 0380-0903


  121 in total

Review 1.  Risks and benefits of nonsteroidal anti-inflammatory drugs in children: a comparison with paracetamol.

Authors:  C Litalien; E Jacqz-Aigrain
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  Present concepts on the inflammatory modulators with special reference to cytokines.

Authors:  A S J P A M Van Miert
Journal:  Vet Res Commun       Date:  2002-02       Impact factor: 2.459

Review 3.  Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease.

Authors:  P L McGeer
Journal:  Drugs Aging       Date:  2000-07       Impact factor: 3.923

4.  Selective visualization of cyclooxygenase-2 in inflammation and cancer by targeted fluorescent imaging agents.

Authors:  Md Jashim Uddin; Brenda C Crews; Anna L Blobaum; Philip J Kingsley; D Lee Gorden; J Oliver McIntyre; Lynn M Matrisian; Kotha Subbaramaiah; Andrew J Dannenberg; David W Piston; Lawrence J Marnett
Journal:  Cancer Res       Date:  2010-05-01       Impact factor: 12.701

Review 5.  Therapies targeting lipid peroxidation in traumatic brain injury.

Authors:  Tamil Selvan Anthonymuthu; Elizabeth Megan Kenny; Hülya Bayır
Journal:  Brain Res       Date:  2016-02-10       Impact factor: 3.252

6.  Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling.

Authors:  Dan A Dixon; Neal D Tolley; Kristi Bemis-Standoli; Mark L Martinez; Andrew S Weyrich; Jason D Morrow; Stephen M Prescott; Guy A Zimmerman
Journal:  J Clin Invest       Date:  2006-09-21       Impact factor: 14.808

7.  Novel glycoside from Wedelia calendulacea inhibits diethyl nitrosamine-induced renal cancer via downregulating the COX-2 and PEG2 through nuclear factor-κB pathway.

Authors:  Amita Verma; Bahar Ahmed; Firoz Anwar; Mahfoozur Rahman; Dinesh Kumar Patel; Gaurav Kaithwas; Ravi Rani; Prakash C Bhatt; Vikas Kumar
Journal:  Inflammopharmacology       Date:  2017-02-02       Impact factor: 4.473

8.  Selenium inhibits LPS-induced pro-inflammatory gene expression by modulating MAPK and NF-κB signaling pathways in mouse mammary epithelial cells in primary culture.

Authors:  Wen Zhang; Runxiang Zhang; Tiancheng Wang; Haichao Jiang; Mengyao Guo; Ershun Zhou; Yong Sun; Zhengtao Yang; Shiwen Xu; Yongguo Cao; Naisheng Zhang
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

9.  Pharmacokinetic-pharmacodynamic modelling of the analgesic effects of lumiracoxib, a selective inhibitor of cyclooxygenase-2, in rats.

Authors:  D A Vásquez-Bahena; U E Salazar-Morales; M I Ortiz; G Castañeda-Hernández; Iñaki F Trocóniz
Journal:  Br J Pharmacol       Date:  2009-12-02       Impact factor: 8.739

10.  The anti-inflammatory effect of Cheongseoikki-tang ethanol extract on allergic reactions mediated by bone marrow-derived mast cells.

Authors:  Joon-Ho Keum; Ok-Hwa Kang; Sung-Bae Kim; Su-Hyun Mun; Yun-Soo Seo; Ma-Ryong Kim; Jung-Rae Rho; Young-Seob Lee; Chung-Berm Park; Young-Guk Kim; Yong-Il Kim; Sin-Hee Han; Dong-Yeul Kwon
Journal:  Chin J Integr Med       Date:  2013-03-15       Impact factor: 1.978

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.